Browsing Centre for Clinical Pharmacology by Author "Hackinger, S"
Now showing items 1-4 of 4
-
Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study
Mamakou, V; Hackinger, S; Zengini, E; Tsompanaki, E; Marouli, E; Serafetinidis, I; Prins, B; Karabela, A; Glezou, E; Southam, L (2018-08-02) -
Evaluating the glucose raising effect of established loci via a genetic risk score.
Marouli, E; Kanoni, S; Mamakou, V; Hackinger, S; Southam, L; Prins, B; Rentari, A; Dimitriou, M; Zengini, E; Gonidakis, F (2017)Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with glucose levels. We tested the hypothesis here whether the cumulative effect of glucose raising SNPs, ... -
Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia.
Hackinger, S; Prins, B; Mamakou, V; Zengini, E; Marouli, E; Brčić, L; Serafetinidis, I; Lamnissou, K; Kontaxakis, V; Dedoussis, G (2018-11-23)The epidemiologic link between schizophrenia (SCZ) and type 2 diabetes (T2D) remains poorly understood. Here, we investigate the presence and extent of a shared genetic background between SCZ and T2D using genome-wide ... -
Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes
Mahajan, A; Wessel, J; Willems, SM; Zhao, W; Robertson, NR; Chu, AY; Gan, W; Kitajima, H; Taliun, D; Rayner, NW (Nature Research (part of Springer Nature), 2018-04-09)We aggregated coding variant data for 81,412 type 2 diabetes cases and 370,832 controls of diverse ancestry, identifying 40 coding variant association signals (P < 2.2 × 10−7); of these, 16 map outside known risk-associated ...